Fulltext

Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study

Zürcher, R. M. ; Bock, H. A. ; Thiel, G.

In: Nephrology Dialysis Transplantation, 1994, vol. 9, no. 5, p. 548-551

Add to personal list
    Title
    • Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study
    Author
    • Zürcher, R. M.. Division of Nephrology, Department of Medicine, University Hospital Basal, Switzerland
    • Bock, H. A.. Division of Nephrology, Department of Medicine, University Hospital Basal, Switzerland
    • Thiel, G.. Division of Nephrology, Department of Medicine, University Hospital Basal, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Nephrology Dialysis Transplantation, 1994, vol. 9, no. 5, p. 548-551. Oxford University Press
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:299892
    Summary
    Patients on cyclosporin A (CsA) often develop hyperuricaemia and gout. In transplant patients the use of uricosuric drugs for treating hyperuricaemia may be preferable to allopurinol because of the known interaction of the latter with azathioprine. We therefore prospectively studied the uricosuric efficacy of 100 mg benzbromarone (Bbr;Desuric®) daily in 25 CsA-treated renal transplant patients with stable graft function and hyperuricaemia (>359 μmol/l for females, >491 μmol/l for males). Benzbromarone decreased plasma uric acid from 579±18 μmol/l to 313±24 μmol/l (mean±SEM; P<0.001) and thereby normalized plasma uric acid in 21 of 25 patients. The remaining four patients had creatininc clearances between 21 and 25 ml/min, the lowest of the entire study group. Mean fractional clearance of uric acid increased from 5.4±0.4% to 17.2±1.0% (P<0.001). The relative decrease of plasma uric acid closely correlated with baseline creatinine clearance (r=0.67; P<0.001). CsA trough values were not influenced. None of the patients experienced any significant side-effects. As an unexpected find-ing, urinary uric acid excretion increased from 2082 ± 175 μmol7sol;24 h to 3233 ±232 μmol/24 h after 4 weeks' treatment with benzbromarone. In conclusion, benzbromarone normalized plasma uric acid in all CsA-treated renal transplant recipients with a creatinine clearance >25 ml/min. Due to its excellent efficacy and lack of significant side-effects, benzbromarone appears to be preferable to allopurinol in CsA-treated renal transplant recipients with a creati nine clearance over 25 ml/min